
Supplementary Materials for

Pharmacological targeting of Tripartite Motif Containing 24 for the
treatment of glioblastoma

Mingzhi Han

Correspondence to: mingzhi.han@sdu.edu.cn

Figures. S1 to S3
Tables S1




Figure S1. (Related to Fig.1B). Graphic representation of tumoursphere formation assays for GSCs treated with different concentrations of dTRIM24 (0 - 10 μ M) (A) or IACS-9571 (0 - 20 μ M) (B) for 6 days. Scale bar = 500 μ m. For the tumoursphere formation assay, GSCs single-cell suspensions (1000 cells/mL/well) were seeded in 6-well ultra-low adhesion plates (Corning Inc., USA) and cultured in Neurobasal medium supplements and growth factors. Inverted phase contrast microscopy (Nikon; Japan) was used to count and acquire images of the tumourspheres. (C) For the in vitro extreme limiting dilution assay, GSCs were placed in a 96-well plate at a density of 1 to 50 cells/well with six replicates for each concentration. After ten days, the numbers of tumourspheres in each well were determined, and the sphere formation efficacy was calculated using extreme limiting dilution analysis software

(<http://bioinf.wehi.edu.au/software/elda/>). Statistical significance was determined by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.






Figure S3. (Related to Fig.1F). Overexpression of SOX2 (SOX2-OE) in GBM#P3 confirmed by western blot assay. GAPDH was used as an internal normalization control. The full-length ORF of the gene was cloned into pENTER vectors. Transfection was performed with Lipofectamine 3000 (Life Technologies, CA).

Supplementary Table S1. STR profile information of primary GBM cells used in this study.

Sample No. GBM#P3	
Marker	Allele
D19S433	16,2
D5S818	10,11
D21S11	31.2,33.2
D18S51	12,15
D6S1043	12,18
AMEL	X,Y
D3S1358	14,16
D13S317	11,12
D7S820	14
D16S539	11,12
CSF1PO	10,12
Penta D	10,11
D2S441	11
vWA	16,17
D8S1179	14,15
TPOX	8
Penta E	5,15
TH01	9
D12S391	19,26
D2S1338	17,23
FGA	23,25

Sample No : GBM#BG7	
Marker	Allele
D3S1358	15,17
TH01	9,9,3
D21S11	31.2,32.2
D18S51	12
Penta E	16,17
D5S818	12
D13S317	8
D7S820	10
D16S539	12,13
CSF1PO	11,13
Penta D	10,13
AMEL	X
vWA	14,19
D8S1179	14
TPOX	8
FGA	21,22
D19S433	12,13
D12S391	20,21
D6S1043	11,20
D2S1338	17,20
D1S1656	17.3

Sample No : GBM#BG5	
Marker	Allele
D3S1358	18,19
TH01	9
D21S11	29,32.2
D18S51	13,18
Penta E	7,11
D5S818	11,13
D13S317	11,13
D7S820	10
D16S539	10,11
CSF1PO	10,11
Penta D	9,13
AMEL	X
vWA	15,16
D8S1179	8,10
TPOX	8
FGA	19,21
D19S433	14,15
D12S391	23
D6S1043	11,14
D2S1338	17,21
D1S1656	12

Sample No : CBM#06	
Marker	Allele
D3S1358	14,15
TH01	6,9,3
D21S11	28,29
D18S51	16
Penta E	12
D5S818	12,13
D13S317	12
D7S820	10,11
D16S539	9,10
CSF1PO	11
Penta D	13,14
AMEL	X,Y
vWA	16
D8S1179	13
TPOX	8,11
FGA	21
D19S433	15
D12S391	17.3
D6S1043	12
D2S1338	18
D1S1656	11,12